Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

ACVR2A downregulation disrupts the TCF7/c-JUN pathway, impairing trophoblast invasion and proliferation in pre-eclampsia, revealing a genetic susceptibility-associated mechanism of placental ...